November is soonest Pfizer can seek COVID vaccine OK

COVID-19 Record coronavirus cases in Russia as it approves second vaccine

By Reuters• 15 October 2020

COVID-19 Record coronavirus cases in Russia as it approves second vaccine By Reuters• 15 October 2020

Pfizer CEO Albert Bourla has long said it's possible that testing might reveal by the end of October whether his company's vaccine actually protects against the coronavirus.

The healthcare chain is also training its staff at 4,000 pharmacies on inoculation through a certification course which is scheduled next month, Apollo Hospitals executive vice-chairperson Shobana Kamineni said.

Pfizer won't apply for FDA emergency use authorization before the third week of November, Bourla wrote in an open letter on Friday.

China has said that while reasonable profits for companies are permitted, Covid-19 vaccines should be priced close to cost.

Samir Deb, pharmaceutical professional, consultant vaccine and public affairs consultant, Southeast Asia, said, "Proven success factors of H1N1 and Ebola have turned out guiding principles in Covid-19 vaccine development".

Bourla noted, "The timelines above reflect our best estimates of when these important milestones could be achieved".

Trick-or-treating is safety risk, county says
Traveling to a rural fall festival that is not in your community if you live in an area with community spread of COVID-19. MDHHS encouraged residents to host virtual Halloween parties instead of in-person.

This is the first time any "leading Western vaccine developer provided such a specific timeline", according to the Wall Street Journal. This would allow the companies to file for an emergency use authorization. "It has said that it may have interim data on its 30,000 person trial as soon as November", as reported by Reuters.

This comes at a time when COVID-19 cases in the USA are climbing slightly, but the coronavirus deaths are relatively level this month. The company pointed out that illnesses, even severe cases, "are an expected part of any clinical study, especially large studies". And that information will be ready before the safety readout, he said.

Though President Trump and others have portrayed it as a silver bullet in bringing the rampaging deadly virus to an end, epidemiologists and vaccine researchers tend to portray any COVID-19 vaccine more as one effective tool among many in the fight against the spread of the disease. Even if that were so, a pre-election vaccine would mean the Food and Drug Administration would have to give an nearly immediate thumbs-up. "Distribution will begin within 24 hours", President Trump said.

Polls show many Americans are hesitant about taking a coronavirus vaccine and concerned that the approval process could be driven by politics.

White Paper: Why Test Your COVID-19 Therapies for Auditory Safety?

The first patient enrolled in Pfizer's COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore received an injection in May. The agreement provides the USA government an option to purchase an additional 500 million doses.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.